These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38346907)

  • 1. Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome.
    Kravchenko L; Unhurian L; Tiuzhinska SK; Ivanova Y; Obrazenko M; Zahorodnya L; Yamilova T
    Ceska Slov Farm; 2024; 72(6):297-303. PubMed ID: 38346907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
    Kargiotis K; Katsiki N; Athyros VG; Giouleme O; Patsiaoura K; Katsiki E; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2014 May; 12(3):505-11. PubMed ID: 24805248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome.
    Esmail VAW; Mohammed MO; Al-Nimer MSM
    Arab J Gastroenterol; 2021 Mar; 22(1):1-5. PubMed ID: 33664007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
    Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
    J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimization of long-term treatment with rosuvastatin of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
    Skrypnyk IM; Dubrovins'ka TV
    Lik Sprava; 2014; (5-6):113-21. PubMed ID: 25906659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
    Georgian Med News; 2014 Apr; (229):53-8. PubMed ID: 24850606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INFLUENCE OF COMPLEX TREATMENT ON BIOCHEMICAL BLOOD PARAMETERS OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT PRE-DIABETES.
    Feysa SV; Rudakova SO
    Wiad Lek; 2021; 74(4):986-991. PubMed ID: 34156017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds.
    Ragab SM; Abd Elghaffar SKh; El-Metwally TH; Badr G; Mahmoud MH; Omar HM
    Lipids Health Dis; 2015 Jul; 14():83. PubMed ID: 26228038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.
    Mitsiou E; Boutari C; Kotsis V; Georgianou E; Doumas M; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2018; 16(4):393-400. PubMed ID: 28669329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome.
    Augusto CT; de la Paz Scribano Parada M; Rossi MM; Signorini F; Fonseca I; Del Carmen Baez M
    Antiinflamm Antiallergy Agents Med Chem; 2023; 21(3):194-203. PubMed ID: 36815659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
    Han AL
    BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Carnevale R; Bartimoccia S; Nocella C; Baratta F; Loffredo L; Pignatelli P; Violi F; Angelico F
    BMC Gastroenterol; 2014 Apr; 14():81. PubMed ID: 24758604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFICACY OF COMPREHENSIVE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PREDIABETES.
    Ivachevska VV; Ivachevskyi MM; Hechko MM; Myhovych II; Blaga OS
    Wiad Lek; 2023; 76(3):581-585. PubMed ID: 37057783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
    Surapaneni KM; Priya VV; Mallika J
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combined Intervention with Germinated Vigna radiata and Aerobic Interval Training Protocol Is an Effective Strategy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Other Alterations Related to the Metabolic Syndrome in Zucker Rats.
    Kapravelou G; Martínez R; Nebot E; López-Jurado M; Aranda P; Arrebola F; Cantarero S; Galisteo M; Porres JM
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28753963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.
    Souza MR; Diniz Mde F; Medeiros-Filho JE; Araújo MS
    Arq Gastroenterol; 2012; 49(1):89-96. PubMed ID: 22481692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.